Fatma Peyman ERTUĞ, Erğin ŞİNGİRİK, Hacer Sinem BÜYÜKNACAR, Cemil GÖÇMEN, Mehmet Ata SEÇİLMİŞ

Pharmacological profile of a nitric oxide donor spermine NONOate in the mouse corpus cavernosum

To investigate the effects of spermine NONOate in the cavernous tissue obtained from mice treated or untreated with sildenafil. Materials and methods: We studied the effects of spermine NONOate on the tone and nitrergic relaxation responses of isolated mouse corpus cavernosum and compared them with sodium nitroprusside in the absence or presence of L-nitroarginine, hydroxocobalamin, pyrogallol, diethyldithiocarbamate (DETCA), or 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). The neurogenic contractions and relaxations of the tissues were induced by electrical field stimulation. Some mice received a single oral dose of sildenafil and after 1 h the effects of spermine NONOate were evaluated by in vitro studies. Results: Spermine NONOate relaxed mouse corpus cavernosum in a concentration-dependent manner. Spermine-NONOate-induced relaxation was relatively slow to develop and it was reversible and reproducible. These relaxations were significantly suppressed by hydroxocobalamin, diethyldithiocarbamate, or ODQ, but not by L-nitroarginine or pyrogallol. Spermine NONOate potentiated the nitrergic relaxations to electrical field stimulation (EFS), whereas it significantly reduced EFS-induced contractions. Sildenafil treatment can enhance the relaxant responses to spermine NONOate and EFS. Conclusion: These findings suggest that spermine NONOate has a potent relaxant action in cavernous tissue and this effect can be potentiated by oral sildenafil treatments. Spermine NONOate may be considered an attractive treatment for erectile dysfunction in pathologic disorders with a lack of endogenous NO production.

Anahtar Kelimeler:

Key words: EFS, electrical field stimulation, L-NOARG, N-nitro-L-arginine, spermine NONOate, S-NONOate

Pharmacological profile of a nitric oxide donor spermine NONOate in the mouse corpus cavernosum

Keywords:

Key words: EFS, electrical field stimulation, L-NOARG, N-nitro-L-arginine, spermine NONOate, S-NONOate,

PDF

___

Saenz de Tejada I. Nitric oxide as a mediator of relaxation of the corpus cavernosum. N Engl J Med 1992; 326: 1638.
Saenz de Tejada I. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res 2004; 16: S40–S42.
Ulvi H, Aygül R, Demir R. Effect of L-carnitine on diabetic neuropathy and ventricular dispersion in patients with diabetes mellitus. Turk J Med Sci 2010; 40: 169–175.
Yalçınkakaya FR, Davarcı M, Akcin S, Gokce A, Guven EO, İnci M, Balbay MD. Urodynamic evaluation of acute effects of sildenafil on voiding among males with erectile dysfunction and symptomatic benign prostate. Turk J Med Sci 2012; 42: 951–995.
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, for The Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.
Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164–2171.
Saenz De Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159–2164.
Goldstein I, Young JM, Fıscher J, Bangerter K, Segerson T, Taylor T, The Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. Diabetes Care 2003; 26: 777–783.
Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998; 53: 123–127.
Kalsi JS, Rees RW, Hobbs AJ, Royle M, Kell1 PD, Ralph DJ, Moncado S, Cellek S. Bay41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol 2003; 169: 761–766.
Salom JB, Barbera MD, Centeno JM, Orti M, Torregrosa G, Albroch E. Relaxant effects of sodium nitroprusside and NONOates in rabbit basilar artery. Pharmacol 1998; 57: 79–87.
De Witt BJ, Marrone JR, Kaye AD, Keefer LK, Kadowitz PJ. Comparison of responses to novel nitric oxide donors in the feline pulmonary vascular bed. Eur J Pharmacol 2001; 430: 311–315.
Keefer LK, Nims RW, Davies KM, Wink DA. “NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Methods Enzymol 1996; 268: 281–293.
Göçmen C, Büyüknacar SG, Kots A, Murad F, Kıroğlu OE, Kumcu EK. The relaxant activity of 4,7-dimethyl-1,2,5oxadiazolo[3,4-d]-pyridazine1,5,6-trioxide in the mouse corpus cavernosum. J Pharmacol Exp Ther 2006; 316: 753–761.
Göçmen C, Uçar P, Şingirik E, Dikmen A. An in vitro study of nonadrenergic-noncholinergic activity on the cavernous tissue of mouse. Urol Res 1997; 25: 269–275.
Göçmen C, Seçilmiş A, Uçar P, Karataş Y, Önder S, Dikmen A, Baysal F. A possible role of S-nitrosothiols at the nitrergic relaxations in the mouse corpus cavernosum. Eur J Pharmacol 1998; 361: 85–92.
Göçmen C, Göktürk HS, Ertuğ PU, Önder S, Dikmen A, Baysal F. Effect of neocuproine, a selective Cu(I) chelator, on nitrergic relaxations in the mouse corpus cavernosum. Eur J Pharmacol 2000; 406: 293–300.
Sezen SF, Burnett AL. Intracavernosal pressure monitoring in mice: responses to electrical stimulation of the cavernous nerve and to intracavernosal drug administration. J Androl 2000; 21: 311–315.
Homer KL, Wanstall JC. Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor. Br J Pharmacol 2000; 131: 673–682.
Miller MR, Okubo K, Roseberry MJ, Webb DJ, Megson IL. Extracellular nitric oxide release mediates soluble guanylate cyclase-independent vasodilator action of spermine NONOate: comparison with other nitric oxide donors in isolated rat femoral arteries. J Cardiovasc Pharmacol 2004; 43: 440–451.
Rajanayagam MAS, Li CG, Rand MJ. Differential effects of hydroxocobalamin on NO-mediated relaxations in rat aorta and anococcygeus muscle. Br J Pharmacol 1993; 108: 3–5.
Gillespie JS, Sheng H. The effects of pyrogallol and hydroquinone on the response to NANC nerve stimulation in the rat anococcygeus and the bovine retractor penis muscles. Br J Pharmacol 1990; 99: 194–196.
Ignarro LJ, Byrns RE, Buga GM, Wood KS, Chaudhuri G. Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxideelicited vascular smooth muscle relaxation. J Pharmacol Exp Ther 1988; 244: 181–189.
Omar HA, Cherry PD, Mortelliti MP, Burke-Wolin T, Wolin MS. Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. Circ Res 1991; 69: 601–608.
Lefebvre RA. Influence of superoxide dismutase inhibition on the discrimination between NO and the nitrergic neurotransmitter in the rat gastric fundus. Br J Pharmacol 1996; 118: 2171–2177.
Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90–94.
Kalsi JS, Kell1 PD, Cellek S, Ralph DJ. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. Int J Impot Res 2004; 16: 195–200.
Cellek S, Moncada S. Modulation of noradrenergic responses by nitric oxide from inducible nitric oxide synthase. Nitric Oxide 1997; 1: 204–210.
Li CG, Rand MJ. Evidence for a role of nitric oxide in the neurotransmitter system mediating relaxation of the rat anococcygeus muscle. Clin Exp Pharmacol Physiol 1989; 16: 933–938.
Kasakov L, Cellek S, Moncada S. Characterization of nitrergic neurotransmission during short-and long-term electrical stimulation of the rabbit anococcygeus muscle. Br J Pharmacol 1995; 115: 1149–1154.
Senbel AM, Hashad A, Sharabi FM, Daabees TT. Activation of muscarinic receptors inhibits neurogenic nitric oxide in the corpus cavernosum. Pharmacol Res 2012; 65: 303–311.